Re-LuPSMA: Interim Safety of a Ph II Trial of 177Lu-PSMA-617 Retreatment in mCRPC @urotoday #ESMO26 @CalaisJeremie

📌n=20/40
📌Median retreatment cycles: 3 (IQR 2–5)
📌165 AEs, 88 possibly TR: Gr1 (n=53); Gr2 (n=14); Gr3 (n=13); Gr 4 (n=8)
📌Most common TRAEs: leukopenia (n=12), anemia (n=15), thrombocytopenia (n=10), xerostomia (n=10)